Diabetic retinopathy and health-related quality of life

Davidov, Eldad; Breitscheidel, Lusine; Clouth, Johannes; Reips, Marion; Happich, Michael

doi:10.1007/s00417-008-0960-y

Cited by 60 publications

(60 citation statements)

References 24 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, few studies have been performed to explore the relationship between DME and HRQoL. Among a handful of studies performed, DME was shown to have a significant impact on the HRQoL in patients with diabetes [45][46][47] .…”

Section: Humanistic Burdenmentioning

confidence: 98%

“…Another analysis of 207 type 1 and type 2 patients diagnosed with diabetic retinopathy from Germany showed that DME displayed a strong negative effect on visual acuity and on the mental components of a generic questionnaire (SF-12). In addition, the severity of DME was positively associated with binocular vision acuity as well as impaired HRQoL 46 .…”

Section: Humanistic Burdenmentioning

confidence: 99%

See 1 more Smart Citation

Burden of illness of diabetic macular edema: literature review

Er¹,

Looman²,

Laouri³

et al. 2010

Current Medical Research and Opinion

127

100

View full text Add to dashboard Cite

show abstract

Section: Humanistic Burdenmentioning

confidence: 98%

Section: Humanistic Burdenmentioning

confidence: 99%

Burden of illness of diabetic macular edema: literature review

Er¹,

Looman²,

Laouri³

et al. 2010

Current Medical Research and Opinion

127

100

View full text Add to dashboard Cite

show abstract

“…Several studies have demonstrated both a qualitative and a quantitative reduction in health related quality of life in persons with DR [3,8,9]. But no such study has been done in the Indian population.…”

mentioning

confidence: 99%

Quality of Life in People with Diabetic Retinopathy: Indian Study

Pereira

Shah

D'Souza

et al. 2017

JCDR

View full text Add to dashboard Cite

“…Several studies have demonstrated that quality of life (QoL) among DME patients is greatly affected at all stages of disease, from preliminary symptoms to diagnosis to vision loss. [1][2][3][4] Treatment of DME may improve vision-related QoL in these patients. 3,5 The importance of identifying safe and effective treatments for DME that result in anatomic, functional, and QoL improvements is underscored by the rising prevalence of diabetesestimated to affect more than 350 million individuals worldwide by 2030.…”

mentioning

confidence: 99%

Changes in Vision- and Health-Related Quality of Life in Patients with Diabetic Macular Edema Treated with Pegaptanib Sodium or Sham

Loftus

Sultan

Pleil

2011

Invest. Ophthalmol. Vis. Sci.

View full text Add to dashboard Cite

PURPOSE. To compare vision function and self-reported quality of life (QoL) in patients with diabetic macular edema (DME) treated with intravitreous pegaptanib 0.3 mg or sham injection. METHODS. This randomized (1:1), controlled, multicenter trial included subjects with DME (center point thickness on OCT, Ն250 m) and visual acuity (VA) Յ65 letters and Ն35 letters. In year 1, pegaptanib or sham was administered every 6 weeks with focal/grid photocoagulation at investigator discretion after week 18. Subjects received injections as often as every 6 weeks per pre-specified criteria in year 2. Primary efficacy endpoint: proportion gaining Ն10 letters of VA from baseline to week 54. Change in QoL from baseline to weeks 54 and 102 was assessed with the 25-item National Eye Institute-Visual Function Questionnaire (NEI-VFQ 25) and the EQ-5D. RESULTS. One hundred thirty-three pegaptanib-and 127 shamtreated subjects were in the year 1 intent-to-treat population. (QoL) among DME patients is greatly affected at all stages of disease, from preliminary symptoms to diagnosis to vision loss.1-4 Treatment of DME may improve vision-related QoL in these patients. 3,5The importance of identifying safe and effective treatments for DME that result in anatomic, functional, and QoL improvements is underscored by the rising prevalence of diabetesestimated to affect more than 350 million individuals worldwide by 2030.6 Among adults with diabetes, approximately 1 in 10 experiences vision-threatening diabetic retinopathy; half (5.7% of all diabetics) go on to develop DME, 7 a condition responsible for 4.8% of blindness worldwide.8 Until recently, laser photocoagulation has been the standard treatment for DME, but vascular endothelial growth factor inhibitors have produced impressive gains in visual acuity during up to 2 years of follow-up in treating this condition (Radhakrishnan R, et al. IOVS 2010;52:ARVO E-Abstract 5042).9 -15 A recent study 14 found intravitreal (IVT) injections of pegaptanib sodium 0.3 mg to be a well-tolerated and effective treatment for DME. The study demonstrated a statistically significant difference in favor of pegaptanib over sham injection in the proportion of subjects with Ն10 letters (or 2 lines) visual acuity (VA) improvement at week 54 (primary endpoint). Improvement of at least 10 letters from baseline to week 54 was achieved by 36.8% (49/133) of subjects treated with pegaptanib compared with 19.7% (25/ 127) of sham-treated subjects (odds ratio [95% CI]: 2.38 [1.32-4.30]; P ϭ 0.0047). The clinical benefit of pegaptanib treatment for DME was further supported by statistically significant differences favoring pegaptanib with regard to several secondary endpoints (e.g., degree of retinopathy, use of focal/grid laser treatment). As part of the pivotal trial of pegaptanib in DME, changes in QoL over 54 and 102 weeks were evaluated by using the condition-specific 25-item National Eye Institute Visual Function Questionnaire (NEI-VFQ 25) and the EuroQol five-dimension (EQ-5D) health status measure. Results of thos...

show abstract

Diabetic retinopathy and health-related quality of life

Abstract: Presence of DR and ME, visual acuity impairment and patient co-morbidities lead to significant impairment of both the physical and mental components of HRQOL.

Cited by 60 publications

References 24 publications

Burden of illness of diabetic macular edema: literature review

Burden of illness of diabetic macular edema: literature review

Quality of Life in People with Diabetic Retinopathy: Indian Study

Changes in Vision- and Health-Related Quality of Life in Patients with Diabetic Macular Edema Treated with Pegaptanib Sodium or Sham

Contact Info

Product

Resources

About